CHO Pharma Past Earnings Performance

Past criteria checks 0/6

CHO Pharma has been growing earnings at an average annual rate of 3.5%, while the Pharmaceuticals industry saw earnings growing at 8.2% annually. Revenues have been growing at an average rate of 9.5% per year.

Key information

3.5%

Earnings growth rate

4.7%

EPS growth rate

Pharmaceuticals Industry Growth	18.5%
Revenue growth rate	9.5%
Return on equity	-8.9%
Net Margin	-23,590.9%
Last Earnings Update	30 Jun 2024

Recent past performance updates

Recent updates

Here's Why We're Not Too Worried About CHO Pharma's (GTSM:6586) Cash Burn Situation

Mar 24

We're Not Very Worried About CHO Pharma's (GTSM:6586) Cash Burn Rate

Dec 09

Revenue & Expenses Breakdown

How CHO Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TPEX:6586 Revenue, expenses and earnings (TWD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Jun 24	1	-255	33	199
31 Mar 24	1	-281	31	219
31 Dec 23	0	-306	30	239
30 Sep 23	0	-317	27	277
30 Jun 23	0	-327	24	315
31 Mar 23	0	-333	24	321
31 Dec 22	0	-338	25	326
30 Sep 22	2	-298	24	284
30 Jun 22	4	-257	23	242
31 Mar 22	4	-232	22	218
31 Dec 21	4	-206	20	194
30 Sep 21	2	-223	21	212
30 Jun 21	0	-240	21	230
31 Mar 21	0	-269	21	259
31 Dec 20	0	-297	22	288
30 Sep 20	0	-328	23	317
30 Jun 20	0	-359	24	347
31 Mar 20	0	-359	24	346
31 Dec 19	0	-358	25	345
30 Sep 19	0	-347	24	335
30 Jun 19	0	-337	23	325
31 Mar 19	0	-322	23	311
31 Dec 18	0	-307	22	297
30 Sep 18	0	-309	27	295
30 Jun 18	0	-312	32	294
31 Mar 18	0	-310	34	291
31 Dec 17	0	-309	35	289
30 Sep 17	1	-293	32	276
30 Jun 17	1	-278	30	264
31 Mar 17	1	-262	25	254
31 Dec 16	2	-245	21	243
30 Sep 16	1	-203	14	211
30 Jun 16	1	-161	7	178
31 Mar 16	0	-135	3	160
31 Dec 15	0	-110	0	141

Quality Earnings: 6586 is currently unprofitable.

Growing Profit Margin: 6586 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 6586 is unprofitable, but has reduced losses over the past 5 years at a rate of 3.5% per year.

Accelerating Growth: Unable to compare 6586's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6586 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.9%).

Return on Equity

High ROE: 6586 has a negative Return on Equity (-8.87%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/02 04:57
End of Day Share Price	2025/01/02 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CHO Pharma, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution